---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-001894"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:44:36.961774+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports Q4 2023 product sales of $5.1M, up 30% YoY; backlog grows to $9.4M

## Summary
- Q4 2023 sales $5.1M vs $3.9M in Q4 2022 (+30.3%); full-year 2023 sales $17.5M vs $18.6M (-5.9%).
- Backlog $9.4M as of Dec 31, 2023, up from $2.5M a year ago, driven by production disruptions from contamination events.
- Production output improved in Nov/Dec 2023, annualizing ~$26.8M; company targeting >$6M quarterly production.
- FDA response on Re-Tain CMC Technical Section expected by May 2024.
- Conference call to discuss full results on Feb 22, 2024.

## SEC filing metadata
- accession: 0001213900-24-001894
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/0001213900-24-001894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/ea191339-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-001894
- JSON: https://secwatch.observer/filing/0001213900-24-001894.json
- Plain text: https://secwatch.observer/filing/0001213900-24-001894.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported preliminary financial results for the fourth quarter of 2023, which ended December 31, 2023.
  - Period: the fourth quarter of 2023, which ended December 31, 2023
  - Result: preliminary results
  source text: On January 8, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/0001213900-24-001894-index.htm
- Earnings Releases
  IMMUCELL CORP /DE/ reported preliminary financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: preliminary results
  source text: On January 8, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/0001213900-24-001894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.